Puma Biotechnology (PBYI) Equity Average (2017 - 2025)
Puma Biotechnology (PBYI) has disclosed Equity Average for 9 consecutive years, with $122.8 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Equity Average rose 50.48% year-over-year to $122.8 million, compared with a TTM value of $122.8 million through Dec 2025, up 50.48%, and an annual FY2025 reading of $111.2 million, up 52.83% over the prior year.
- Equity Average was $122.8 million for Q4 2025 at Puma Biotechnology, up from $110.0 million in the prior quarter.
- Across five years, Equity Average topped out at $122.8 million in Q4 2025 and bottomed at -$6.7 million in Q4 2021.
- Average Equity Average over 5 years is $44.7 million, with a median of $31.3 million recorded in 2023.
- The sharpest move saw Equity Average crashed 108.74% in 2021, then skyrocketed 909.9% in 2023.
- Year by year, Equity Average stood at -$6.7 million in 2021, then soared by 427.37% to $21.9 million in 2022, then soared by 110.64% to $46.1 million in 2023, then soared by 77.05% to $81.6 million in 2024, then surged by 50.48% to $122.8 million in 2025.
- Business Quant data shows Equity Average for PBYI at $122.8 million in Q4 2025, $110.0 million in Q3 2025, and $100.9 million in Q2 2025.